Measuring folate receptor alpha in ovarian, fallopian tube and peritoneal cancer in Italy

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adult women whose high-grade serous ovarian, fallopian tube or primary peritoneal cancer has come back, and who have stored tumor tissue from diagnosis and from the first relapse.

Age

18 years or older

Sex

Women only

Disease stage

Relapsed ovarian, fallopian tube or primary peritoneal cancer; high-grade serous carcinoma on tissue examination

Biomarker or test result

Stored tumor samples must be adequate for the Ventana folate receptor alpha (FOLR1) RxDx assay, as judged by the site pathologist. The study measures folate receptor alpha (FRα) status.

Main reasons for not taking part

• Unclear diagnosis on tissue review
• Diagnosis made from cell tests only, with no biopsy or surgical sample
• Cancer types other than high-grade serous ovarian, fallopian tube or primary peritoneal cancer
• No stored tissue sample available from diagnosis or from the relapse

The registry criteria, word for word

What the trial wants to find out

The purpose of this study is to evaluate the prevalence of folate receptor alpha (FRα)-positive status (≥75% viable tumor cells with moderate (2+) and/or strong (3+) membrane staining) in participants with high-grade serous ovarian, fallopian tube, and primary peritoneal cancer, stratified by time of sampling (initial diagnosis versus relapse), adhering to Ventana folate receptor alpha (FOLR1) RxDx (prescription diagnosis) assay Interpretation Guidance.

The group in the trial

• Folate Receptor Alpha (FRα)

  Samples of eligible participants with ovarian cancer will be analyzed retrospectively for folate receptor alpha (FRα) expression.